IPP Bureau
Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer
By IPP Bureau - September 13, 2022
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
We will vaccinate 100% of the animals by 2025: Narendra Modi
By IPP Bureau - September 13, 2022
The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals
Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
By IPP Bureau - September 12, 2022
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
By IPP Bureau - September 12, 2022
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Thalassemia Sickle Cell Society receives 200000th blood units
By IPP Bureau - September 12, 2022
Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients
Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India
By IPP Bureau - September 12, 2022
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
WuXi STA opens a new sterile lipid nanoparticle formulation facility
By IPP Bureau - September 11, 2022
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
Agilent named among top workplaces by Fortune in healthcare
By IPP Bureau - September 11, 2022
85% of Agilent employees who responded to the survey indicated that the company is a great place to work
Merck invests € 130 million + to strengthen manufacturing capabilities in France
By IPP Bureau - September 10, 2022
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Lupin Launches Generic Suprep Bowel Prep Kit in US
By IPP Bureau - September 10, 2022
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of US $202 mn in the US
Avery Pharmaceuticals starts commercial production of unit at Sanand
By IPP Bureau - September 10, 2022
The plant is a dedicated for manufacturing of Mouth dissolving strip.
Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal
By IPP Bureau - September 10, 2022
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
By IPP Bureau - September 10, 2022
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Vandemark gets investment from SK Capital with Comvest partners
By IPP Bureau - September 09, 2022
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.
By IPP Bureau - September 09, 2022
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
